Develops and sells AI-powered laboratory blood tests for early cancer detection and chronic disease prevention, and provides laboratory access for diagnostics startups.
10-K for FY2025, filed Mar 31, 2026
Customers pay for laboratory blood tests and services, including access to its shared laboratory; the filing describes revenue when customers receive the promised goods or services but does not say when payment is due.
10-K for FY2025, filed Mar 31, 2026In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company recognizes revenue when the customer obtains control…View ↗
The Company’s revenue by contract type is as follows:View ↗
For the Years Ended December 31, 2025 2024 Revenues BioCheck $ 152,047 $ 177,283 OneTest 1,803,707 1,490,881 CLIAx 89,379 84,179 Total…View ↗
$2M
10-K for FY2025, filed Mar 31, 2026
$2M ↗| Segment | Share | Revenue |
|---|---|---|
|
BioCheck
|
7.4% |
BioCheck, FY2025
$152K Sources
|
|
OneTest
|
88% |
OneTest, FY2025
$1.8M Sources
|
|
CLIAx
|
4.4% |
CLIAx, FY2025
$89.4K Sources
|
The company sells tests to firefighters, employers, individual consumers, veterans, fire departments, and physician practices. It markets directly to consumers online and through retail pharmacies, and serves fire departments, employers, and other organizations.
10-K for FY2025, filed Mar 31, 2026 8-K, filed Aug 17, 2026Additionally, on February 26, 2025, the “Firefighter Investments to Recognize Exposure to Cancer Act of 2025” was reintroduced as H.R.…View ↗
Exploit our compelling advantage of at-home and retail collections. We believe that COVID-19 testing caused a paradigm shift in the way…View ↗
Targeting higher-risk populations. We already target firefighters, due to their proven higher incidence and mortality rates for several…View ↗
No. It lost $3.7M in FY2025.
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1.5MView ↗
10-Q for Q2 FY2026, filed Aug 14, 2026
Open tableView ↗
8-K, filed Sep 10, 2026
As previously disclosed, on July 17, 2026, 20/20 Biolabs, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market…View ↗
Competes with Grail, Illumina, Thrive, and Exact Sciences
10-K for FY2025, filed Mar 31, 2026In the U.S., we know of no MCED blood tests that large numbers of Americans routinely utilize. Furthermore, there do not appear to…View ↗
Loading...